USD 9.42 billion
Cardiac Biomarkers Market Size, Share, Growth Analysis, By Product (Troponin, CK-MB), By Application (Acute Coronary Syndrome, Myocardial Infarction), By Location of Testing, By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35A2951 |
Region:
Global |
Published Date: November, 2024
Pages:
199
|Tables:
92
|Figures:
71
Cardiac Biomarkers Market Insights
Global Cardiac Biomarkers Market size was valued at USD 9.42 billion in 2022 and is poised to grow from USD 10.61 billion in 2023 to USD 27.56 billion by 2031, growing at a CAGR of 12.67% during the forecast period (2024-2031).
Cardiac biomarkers are the elements released in blood when the patient’s heart is stressed or damaged. They are necessary for managing and diagnosing different heart associated disorders like heart failures, heart attacks, and more. The cardiac biomarkers market is significantly driven by the growing incidences of heart diseases, increasing awareness regarding the benefits of early diagnosis, mounting demand for personalized medicines, and improvements in biomarker technologies. However, the market is restrained by costly advanced biomarker testing and lack of standardization, leading to variations in test results. Overall, the market is projected to continue progressing due to the growing number of innovations, higher emphasis on preventive healthcare, and rising healthcare expenditure.
Market Snapshot - 2024-2031
Global Market Size
Largest Segment
Laboratory Testing
Fastest Growth
Congestive Heart Failure
Growth Rate
12.67%
Global Cardiac Biomarkers Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Cardiac Biomarkers Market Segmental Analysis
Global Cardiac Biomarkers Market is segmented by Product, Application, Location of Testing, and Region. Based on Product, the market is segmented into Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others. Based on Application, the market is segmented into Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others. Based on Location of Testing, the market is segmented into Laboratory Testing, Point of Care Testing. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Analysis by Product
Based on type, the cardiac biomarkers market is segmented as troponin, CK-MB, myoglobin, BNP and NT-proBNP, and others. The troponin segment held a notable market share in 2023 and is projected to lead over the forecast period owing to high sensitivity and specificity. These tests are specific and highly sensitive for identifying myocardial injury, increasing their significance for diagnosing myocardial infarctions (heart attacks). Also, augmented levels of troponin are known as the gold standard for diagnosis of ACS and are used in clinics. Elevated troponin levels also show myocardial damage in early periods, allowing timely intervention.
Conversely, the BNP and NT-proBNP segment is anticipated to gain a significant market share over the coming years owing to better heart failure management. These biomarkers are essential for managing and diagnosing heart failures, a highly common heart condition. These biomarkers assist in differentiating such failures from other related symptoms. Also, they are associated with poor prediction in patients with heart failures, supporting risk stratification and managing treatment plans. These factors are contributing to the segment’s growth.
Analysis by End-Use
Based on end-use, the market is segmented into laboratory testing, point of care testing. The laboratory testing segment registered for a significant market share in the past years and is expected to lead over the forecast period as well owing to its reliability and high accuracy. Laboratory tests use well-established techniques and devices that offer reliable and accurate outcomes for cardiac biomarkers. They adhere to the quality control measures and standardized protocols, and ensure precise and consistent diagnostic results, thus impacting the market growth.
Conversely, the point of care testing segment is projected to gain a notable market share over the estimated period owing to speedy results and convenience. Point of care testing offers immediate results, enabling treatment decisions and time diagnosis, which is vital for acute care settings and emergency cases. They also enhance accessibility and convenience for patients since they allow testing at the bedside. The said testing also simplifies workflows and reduces diagnosis time, improving clinical efficiency and better patient management.
Global Cardiac Biomarkers Market Size By End-Use
To get detailed analysis on other segments, Request For Free Sample Report
Cardiac Biomarkers Market Regional Insights
Geographically, North America is the dominating region among others and is expected to lead over the forecast period owing to improved healthcare infrastructure with advanced diagnostic technologies and increased adoption of novel medical solutions. Also, the rising incidences of heart disorders in the region are rigorously demanding effective diagnostic solutions. Regional growth is further impacted by robust R&D along with strong network of clinical and academic research institutes, driving improvements in biomarker technologies. The leading players operating in the region include Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Beckman Coulter, Quidel Corporation, and more.
Asia-Pacific is the fastest-growing region in the global cardiac biomarkers market due to the speedy progress made by healthcare infrastructure and heavy investments in healthcare technologies. The market in the region is also driven by mounting cases of cardiovascular diseases due to diabetes, hypertension, and stress. Furthermore, affordability and enhancements in healthcare access are among the significant drivers of the market growth in the region. This, along with emerging market potential and growing geriatric population are driving the market.
Global Cardiac Biomarkers Market Size By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Cardiac Biomarkers Market Dynamics
Drivers
- Focus on Preventive Healthcare and Early Diagnosis
Recent years have increased the awareness levels among a large population base regarding the benefits of early diagnosis of heart disorders. This growing emphasis on cardiovascular conditions and early detection methods to avoid progression and decrease medical costs. Also, improvements in proteomics and genomics allow customized and efficient treatments depending on personal biomarker profiles.
- Automation and Technological Integration
Today, laboratories are increasingly using automation for better outcomes. Automation in such laboratories significantly improves accuracy and efficiency in biomarker testing, increasing accessibility and making them more economic. This will ultimately increase its demand for diagnosis and better patient results. The development of POC testing devices enables convenient and speedy examination, impacting demand in home and clinical settings.
Restraints
- Challenges in Biomarker Reliability and Validation
Validating novel biomarkers requires extensive longitudinal studies and clinical trials, which could consume a lot of time. This may notably hamper and avoid validation of biomarkers, hampering the market growth. They may also show inconsistent results, thus restraining market growth. variability in the levels of biomarkers because of factors like comorbidities and patient demographics may impact the reliability of test results.
- Integration and Data Management Issues
The interpretation and integration of huge quantities of biomarker information may be difficult and need improved tools like analytics tools and improved data management. Hence, this data overload may restrain the growth of the market. Also, ensuring interoperability and compatibility between electronic health records and diverse diagnostic systems may be challenging and cause issues, hampering market growth.
Request Free Customization of this report to help us to meet your business objectives.
Cardiac Biomarkers Market Competitive Landscape
The global cardiac biomarkers market is a highly competitive global market driven by many international competitors. Prominent corporations with cutting-edge AI and ML technology are Google, IBM, Microsoft, and NVIDIA. To support a wide range of applications across industries, these industry experts concentrate on creating cutting-edge algorithms, scalable platforms, and reliable infrastructure. Rapid advances in technology, strategic alliances, and large expenditures on research and development define the competitive environment.
Top Player’s Company Profiles
- Abbott
- QuidelOrtho Corporation
- Siemens AG
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Biomérieux SA
- Bio-Rad Laboratories, Inc.
- Randox Laboratories Ltd.
- Creative Diagnostics
- Life Diagnostics
- Thermo Fisher Scientific
- Becton, Dickinson and Company
- DiaSorin
- Myriad RBM
- Mindray Medical International Limited
- ReLIA Diagnostic Systems
- Merck KGaA
- Quanterix Corporation
- Eurofins Scientific
- Inova Diagnostics
Recent Developments
- In March 2024, Polymedco obtained 510 (k) clearance by the FDA for its speedy troponin assay as a unit of its Pathfast Biomarker Analyser. The recent FDA approved biomarker identifies the existence of cardiac troponin I, a severe alteration in its concentration indicates myocardial infarction.
- In June 2024, Siemens Healthineers recently made an addition of NT‑proBNPII (PBNPII) assay in its exhaustive cardiac list on Atellica Solution. This will help to better diagnose heart failures. They are stress cardiac biomarkers that are released against amplified ventricular filling pressure.
- In October 2023, Mindray launched two novel NT-proBNP and high-sensitivity troponin I (hs-cTnI) cardiac biomarkers. These biomarkers improve the company’s exceptional cardiac biomarkers collection for managing and diagnosing CVDs.
Cardiac Biomarkers Key Market Trends
- Growing Use of Multi-Biomarker Panels: Recent years have witnessed increased use of panels of biomarkers. This inclination towards biomarker panels rather than single markers is trending in the market. These panels offer a highly exhaustive evaluation of cardiovascular risks relating to stress, cardiac injury, and inflammation. Multi-biomarkers methods are currently being explored to improve risk stratification, mainly in complicated cases where single biomarkers may not offer enough data.
- Cardiac Myeloperoxidase (MPO): MPO or cardiac myeloperoxidase is an enzyme freed by activated neutrophils and is engaged in oxidative inflammation and stress. Amplified myeloperoxidase levels may denote signs of myocardial inflammation and could be beneficial in evaluating the risk of different cardiovascular ailments. The latest studies say that the MPO levels can also aid in stratifying threats in individuals with ACS and projecting results.
Cardiac Biomarkers Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the cardiac biomarkers market is being driven by factors like regional expansion and growth of developing economies, expanding use of biomarkers, and growing education and awareness on severe cardiac disorders among the public. However, the factors hampering the growth of the market include privacy and ethical concerns, growing competition from alternate diagnosing techniques, and integration issues. North America is predicted to lead the market owing to the strong regulatory environment, robust research and development, and growing cases of heart diseases. Yet, the market is poised to grow considerably in the coming years due to opportunities like the growing number of training and education programs, the growing number of strategic alliances, and the emphasis on preventive healthcare.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 9.42 billion |
| Market size value in 2031 | USD 27.56 billion |
| Growth Rate | 12.67% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Cardiac Biomarkers Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Cardiac Biomarkers Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Cardiac Biomarkers Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Cardiac Biomarkers Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Cardiac Biomarkers Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Cardiac Biomarkers Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
